In Wednesday’s Wall Street session, Sangamo Therapeutics Inc (NASDAQ:SGMO) shares traded at $0.58, up 13.27% from the previous session.
SGMO stock price is now -0.33% away from the 50-day moving average and -49.45% away from the 200-day moving average. The market capitalization of the company currently stands at $142.82M.
With the price target maintained at $7, Truist recently Upgraded its rating from Hold to Buy for Sangamo Therapeutics Inc (NASDAQ: SGMO). On December 10, 2024, H.C. Wainwright reiterated its ‘Buy’ rating on the stock and kept its target price maintained at $10, while ‘RBC Capital Mkts’ rates the stock as ‘Sector Perform’
A total of 3.28% of the company’s stock is owned by insiders.
During the past 12 months, Sangamo Therapeutics Inc has had a low of $0.30 and a high of $3.18. As of last week, the company has a debt-to-equity ratio of 5.07, a current ratio of 0.76, and a quick ratio of 0.76. The fifty day moving average price for SGMO is $0.5838 and a two-hundred day moving average price translates $1.15165 for the stock.
The latest earnings results from Sangamo Therapeutics Inc (NASDAQ: SGMO) was released for 2025-03-31. The net profit margin was -126.63% and return on equity was -262.12% for SGMO. The company reported revenue of $6.44 million for the quarter, compared to $0.48 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 1238.25 percent. For the current quarter, analysts expect SGMO to generate $29.9M in revenue.
